Maxilene (Lidocaine 4% Cream)
Topical anesthetic cream for numbing skin before medical procedures
Quick Facts About Maxilene
Key Takeaways About Maxilene
- Effective numbing agent: Maxilene contains 4% lidocaine that numbs the skin within 30-60 minutes under occlusive dressing, providing reliable local anesthesia for needle procedures and minor surgeries
- Suitable for children and adults: Can be used in pediatric patients from 1 month of age under medical guidance, making it particularly useful for reducing needle-related pain and anxiety in children
- Topical application only: For external use on intact skin only; do not apply to broken, inflamed, or infected skin or to mucous membranes, eyes, or ears
- Low systemic absorption: When applied as directed to intact skin, systemic lidocaine absorption is minimal, reducing the risk of systemic side effects
- Time your application: Apply 30-60 minutes before the procedure with an occlusive dressing for best results; the anesthetic effect lasts approximately 1-2 hours after removal
What Is Maxilene and What Is It Used For?
Maxilene is a topical anesthetic cream containing 4% lidocaine (40 mg/g) that provides temporary numbing of the skin. It is used before needle procedures, minor surgical procedures, and dermatological treatments to reduce pain and discomfort at the treatment site.
Maxilene belongs to the class of local anesthetics known as amide-type anesthetics. Lidocaine, the active ingredient, is one of the most widely used local anesthetics worldwide and has been listed on the WHO Model List of Essential Medicines since its inception. The 4% concentration in Maxilene cream is specifically formulated for topical application to intact skin, providing effective surface anesthesia without the need for injection.
The primary mechanism of action involves the reversible blockade of voltage-gated sodium channels in nerve cell membranes. When lidocaine penetrates the skin and reaches the sensory nerve endings (nociceptors) in the dermis, it prevents the generation and conduction of nerve impulses. This results in a temporary loss of sensation in the area where the cream is applied, effectively numbing the skin to painful stimuli such as needle punctures or superficial surgical incisions.
Maxilene is commonly used in the following clinical situations:
- Venipuncture and IV cannulation: Numbing the skin before blood draws, intravenous line placement, or blood donation procedures
- Vaccinations: Reducing pain associated with intramuscular or subcutaneous injections, particularly in pediatric patients
- Minor surgical procedures: Providing topical anesthesia before skin biopsies, mole removals, or suturing of superficial wounds
- Dermatological treatments: Reducing discomfort during laser therapy, chemical peels, microdermabrasion, or dermal filler injections
- Port access: Numbing the skin before accessing implanted venous access devices (ports) in patients undergoing chemotherapy or long-term intravenous therapy
- Lumbar puncture preparation: Providing surface anesthesia before spinal needle insertion in both children and adults
Unlike some other topical anesthetic formulations that contain a combination of lidocaine and prilocaine (such as EMLA cream), Maxilene contains only lidocaine as its active ingredient. This can be advantageous for patients who may have a sensitivity to prilocaine or who are at risk of methemoglobinemia, a condition that prilocaine-containing products can potentially cause, particularly in young infants. The liposomal delivery system used in Maxilene cream is designed to enhance skin penetration and provide reliable anesthesia.
Maxilene is for external use on intact skin only. It should not be used as a substitute for injectable local anesthesia when deeper tissue numbing is required, such as for deep surgical procedures. The depth of anesthesia achieved with topical application is limited to the superficial layers of the skin (approximately 3-5 mm depending on application time and whether occlusion is used).
What Should You Know Before Using Maxilene?
Before using Maxilene, inform your healthcare provider about any allergies to local anesthetics, liver disease, heart conditions, or if you are taking other medications containing lidocaine or similar drugs. Special precautions apply for young children, pregnant women, and patients with certain medical conditions.
Contraindications
Maxilene should not be used in the following situations:
- Known hypersensitivity: Do not use if you have a known allergy to lidocaine, other amide-type local anesthetics (such as bupivacaine, mepivacaine, ropivacaine, or prilocaine), or any of the cream's inactive ingredients
- Broken or damaged skin: Do not apply to wounds, cuts, abrasions, burns, inflamed skin, or areas of active dermatitis or eczema, as this can significantly increase systemic absorption and risk of toxicity
- Mucous membranes: Maxilene cream is not formulated for use on mucous membranes (mouth, nose, genital area, or eyes); specific formulations exist for these applications
- Patients with severe hepatic impairment: Because lidocaine is primarily metabolized in the liver, patients with significant liver disease may be unable to metabolize lidocaine adequately, increasing the risk of systemic toxicity
Warnings and Precautions
Exercise caution and consult your healthcare provider before using Maxilene in the following circumstances:
- Large application areas: Applying the cream over large surface areas or for prolonged periods increases systemic absorption and the risk of lidocaine toxicity. Always follow the recommended maximum application area and duration for your body weight and age
- Patients on antiarrhythmic drugs: Class I antiarrhythmic medications (such as mexiletine or tocainide) have similar mechanisms to lidocaine and concurrent use may increase the risk of additive cardiac effects
- Cardiac conduction abnormalities: Patients with pre-existing conduction disorders (such as heart block) should use Maxilene with caution, although systemic absorption from topical application is typically minimal
- G6PD deficiency: Although the risk of methemoglobinemia from lidocaine alone is extremely low (unlike prilocaine), patients with glucose-6-phosphate dehydrogenase deficiency should inform their healthcare provider
- Avoid eye contact: If the cream accidentally contacts the eyes, rinse immediately with copious amounts of water and seek medical attention, as lidocaine can cause corneal irritation and temporary loss of protective reflexes
- Loss of protective sensation: The numbed area will have reduced sensation to pain and temperature, increasing the risk of accidental injury. Protect the treated area from extreme temperatures and trauma until sensation fully returns
Excessive application of topical lidocaine products (using too much cream, applying to too large an area, or leaving the cream on for too long) can lead to serious systemic lidocaine toxicity. Symptoms of lidocaine toxicity include lightheadedness, dizziness, blurred vision, numbness of the tongue, metallic taste, ringing in the ears, muscle twitching, and in severe cases, seizures and cardiac arrhythmias. If any systemic symptoms occur, remove the cream immediately and seek emergency medical attention.
Pregnancy and Breastfeeding
Lidocaine is classified as a Category B medication in pregnancy by the FDA, meaning that animal reproduction studies have not demonstrated a fetal risk, but there are no adequate and well-controlled studies in pregnant women. The topical application of Maxilene on intact skin results in minimal systemic absorption, and the small amount of lidocaine that reaches the bloodstream is unlikely to pose a significant risk to the developing fetus. However, as a general precaution, Maxilene should only be used during pregnancy when the potential benefit clearly justifies the potential risk.
Lidocaine is excreted in breast milk, but the amounts absorbed systemically from topical application are very small. The trace amounts that may pass into breast milk are considered unlikely to cause any adverse effects in a breastfed infant. Nevertheless, as a precaution, avoid applying Maxilene directly to the breast area and consult your healthcare provider before use if you are breastfeeding.
How Does Maxilene Interact with Other Drugs?
Maxilene (lidocaine 4% cream) has limited drug interactions due to minimal systemic absorption from topical use. However, caution is advised when used concurrently with other local anesthetics, Class I antiarrhythmic drugs, or medications that inhibit lidocaine metabolism (CYP1A2 and CYP3A4 inhibitors).
Because Maxilene is applied topically and systemic absorption is limited, clinically significant drug interactions are uncommon. However, it is important to be aware of potential interactions, particularly when the cream is applied over large areas, for extended periods, or on compromised skin where absorption may be enhanced.
Major Interactions
The following interactions are considered potentially significant and warrant medical supervision:
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Other local anesthetics (e.g., bupivacaine, prilocaine, benzocaine) | Additive systemic toxicity; combined lidocaine exposure may exceed safe thresholds | Avoid concurrent use of multiple local anesthetic products; inform your provider of all anesthetics being used |
| Class I antiarrhythmics (e.g., mexiletine, tocainide, flecainide) | Additive cardiac depressant effects; increased risk of cardiac conduction abnormalities | Use with caution; monitor cardiac rhythm if topical lidocaine is applied over large areas in patients on these medications |
| Class III antiarrhythmics (e.g., amiodarone, dofetilide) | Potential additive effects on cardiac conduction and prolonged QT interval risk | Low risk with topical use; however, inform prescriber if using large amounts |
Minor Interactions
The following interactions are generally of lower clinical significance with topical lidocaine use, but healthcare providers should be informed:
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) | May reduce lidocaine metabolism, potentially increasing systemic levels | Clinically relevant only if significant systemic absorption occurs; generally low risk with topical use on intact skin |
| CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, grapefruit juice) | May reduce lidocaine metabolism via the CYP3A4 pathway | Minimal concern with topical application; relevant primarily for intravenous lidocaine administration |
| Beta-blockers (e.g., propranolol, metoprolol) | May reduce hepatic blood flow and slow lidocaine clearance | Negligible risk with topical cream application; relevant only for systemic lidocaine use |
| Cimetidine | Inhibits hepatic metabolism of lidocaine via CYP enzyme inhibition | Not clinically significant with topical formulations at recommended doses |
For most patients, the risk of clinically significant drug interactions with Maxilene cream is very low because systemic absorption from topical application on intact skin is minimal. The most important precaution is to avoid using multiple lidocaine-containing products simultaneously (such as combining Maxilene cream with a lidocaine patch or spray), as this can lead to cumulative systemic exposure exceeding safe limits. Always tell your healthcare provider about all topical and systemic medications you are using.
What Is the Correct Dosage of Maxilene?
Maxilene cream should be applied in a thick layer to the intact skin at the intended procedure site, then covered with an occlusive dressing for 30-60 minutes before the procedure. The exact amount depends on the size of the area to be treated and the patient's age and weight.
Proper application technique is essential for achieving effective numbing while minimizing the risk of excessive systemic absorption. The cream should be applied as a thick, uniform layer over the intended treatment area and then covered with an occlusive dressing (such as a transparent adhesive film dressing, plastic wrap, or specialized dressing) to enhance skin penetration and prevent the cream from being wiped off.
Adults
Adult Dosage Guidelines
- Application amount: Apply approximately 1-2 grams of cream per 10 cm² of skin surface (a thick, uniform layer covering the treatment area)
- Maximum single application area: Do not exceed 600 cm² (approximately 30 x 20 cm) in adults
- Application time with occlusive dressing: 30-60 minutes for venipuncture and superficial procedures; up to 120 minutes for deeper procedures requiring greater depth of anesthesia
- Maximum application time: Do not leave the cream on for more than 2 hours (120 minutes) under occlusive dressing
- Onset of effect: Numbness typically begins within 30 minutes and reaches peak effect at approximately 60 minutes under occlusion
- Duration of effect: Anesthesia persists for approximately 1-2 hours after the cream is removed
Children
Pediatric Dosage Guidelines
- Neonates and infants (1-3 months): Apply up to 1 gram to a maximum area of 10 cm². Maximum application time: 1 hour. Use with caution due to immature hepatic metabolism
- Infants (3-12 months): Apply up to 2 grams to a maximum area of 20 cm². Maximum application time: 1 hour
- Children (1-6 years): Apply up to 10 grams to a maximum area of 100 cm². Maximum application time: 1 hour
- Children (6-12 years): Apply up to 20 grams to a maximum area of 200 cm². Maximum application time: 2 hours
- Adolescents (12+ years): Follow adult dosage guidelines
Note: In pediatric patients, always use the smallest effective amount applied to the smallest possible area for the shortest duration necessary. Children have a higher surface-area-to-body-weight ratio, which increases the risk of systemic absorption relative to adults.
Elderly Patients
No specific dose adjustment is required for elderly patients when Maxilene is used as directed on intact skin. However, elderly patients may have thinner skin, reduced hepatic function, and decreased cardiac output, all of which can increase the potential for systemic absorption and reduced clearance of lidocaine. As a precaution, consider using the lowest effective dose and monitoring for signs of systemic toxicity, particularly in frail elderly patients or those with significant hepatic or cardiac disease.
How to Apply Maxilene
- Wash and dry the area of skin where the procedure will take place
- Apply a thick layer of Maxilene cream to the treatment area without rubbing it in. The cream should be visible as a white layer on the skin
- Cover with an occlusive dressing (such as a transparent adhesive film or plastic wrap secured with tape) to enhance absorption and prevent the cream from being accidentally removed
- Note the application time and leave the dressing in place for the recommended duration (typically 30-60 minutes)
- Remove the dressing and wipe away the remaining cream just before the procedure is to be performed
- The procedure should be performed while the area is still numb (within 1-2 hours of cream removal)
Missed Dose
Maxilene is typically used as a single application before a specific medical procedure, so the concept of a "missed dose" does not apply in the traditional sense. If you forget to apply the cream before arriving at your appointment, inform your healthcare provider. They may choose to apply the cream in the clinical setting with an appropriate waiting period, use an alternative method of local anesthesia (such as an injectable local anesthetic), or reschedule the procedure if topical anesthesia is specifically required and time does not permit adequate application.
Overdose
Overdose from topical lidocaine application is uncommon when the product is used as directed, but can occur if excessive amounts are applied over large areas, if the cream is left on for an extended period, if it is applied to broken or compromised skin, or if it is accidentally ingested. Signs and symptoms of lidocaine overdose may include:
- Central nervous system effects (early): Lightheadedness, dizziness, drowsiness, confusion, blurred vision, tinnitus (ringing in the ears), metallic taste in the mouth, numbness of the tongue and lips
- Central nervous system effects (severe): Muscle twitching, tremors, seizures, loss of consciousness
- Cardiovascular effects (severe): Bradycardia (slow heart rate), hypotension (low blood pressure), cardiac arrhythmias, and in extreme cases, cardiovascular collapse
If you suspect lidocaine overdose or experience any systemic symptoms after using Maxilene, immediately remove the cream and occlusive dressing from the skin, wash the area with soap and water, and seek emergency medical attention. If the cream has been accidentally ingested, do not induce vomiting; contact a poison control center or emergency services immediately. Treatment is supportive and may include airway management, anti-seizure medications, and cardiovascular support.
What Are the Side Effects of Maxilene?
Most side effects of Maxilene are localized to the application site and include mild redness, swelling, blanching, and a transient burning or stinging sensation. Serious systemic side effects are rare when the cream is used as directed on intact skin.
Like all medications, Maxilene can cause side effects, although not everybody gets them. The majority of side effects associated with topical lidocaine application are mild, localized, and self-limiting. Serious adverse reactions are uncommon and are typically associated with excessive use, application to damaged skin, or use in patients with predisposing conditions. The side effects are listed below by frequency category according to international conventions.
Very Common
Affects more than 1 in 10 patients
- Localized skin redness (erythema) at the application site
- Skin pallor or blanching (whitening) at the application site due to local vasoconstriction
- Mild edema (swelling) at the application site
Common
Affects 1 in 10 to 1 in 100 patients
- Burning or stinging sensation during initial application (usually resolves within minutes)
- Itching (pruritus) at the application site
- Sensation of warmth or cold at the application site
- Skin irritation under the occlusive dressing
Uncommon
Affects 1 in 100 to 1 in 1,000 patients
- Allergic contact dermatitis (rash, blistering, or hives at application site)
- Petechiae (small red or purple spots) at the application site
- Purpura (bruising) at the application site
- Altered skin pigmentation (temporary) at the application site
Rare
Affects fewer than 1 in 1,000 patients
- Systemic allergic reactions (urticaria, angioedema, anaphylaxis)
- Methemoglobinemia (extremely rare with lidocaine alone; more associated with prilocaine)
- Systemic lidocaine toxicity (dizziness, drowsiness, seizures, cardiac effects) - typically only with excessive application
- Wound healing impairment (if accidentally applied to broken skin)
The local skin reactions listed above (redness, blanching, mild swelling) are considered normal pharmacological effects of lidocaine on the skin vasculature and nerve endings. They are expected, transient, and generally resolve completely within 1-2 hours after the cream is removed. These reactions are not indicative of an allergy and do not require discontinuation of the product.
True allergic reactions to amide-type local anesthetics like lidocaine are extremely rare, accounting for less than 1% of all adverse reactions attributed to local anesthetics. Most reported "allergies" to local anesthetics are actually vasovagal reactions, anxiety responses, or reactions to preservatives or other inactive ingredients rather than to the anesthetic itself. If you develop widespread hives, facial or throat swelling, or difficulty breathing after applying Maxilene, remove the cream immediately and seek emergency medical care.
Contact your doctor or pharmacist if you experience any side effects that are persistent, severe, or concerning. Seek immediate emergency medical attention if you develop signs of a serious allergic reaction (difficulty breathing, swelling of the face or throat, widespread hives) or symptoms of systemic lidocaine toxicity (dizziness, drowsiness, confusion, blurred vision, ringing in the ears, muscle twitching, or seizures).
How Should You Store Maxilene?
Store Maxilene at room temperature between 15°C and 30°C (59°F to 86°F). Keep the tube tightly closed. Do not freeze. Protect from excessive heat and keep out of reach of children.
Proper storage of Maxilene cream is important to maintain its effectiveness and safety throughout its shelf life. Lidocaine cream formulations are generally stable at room temperature, but exposure to extreme temperatures or improper storage conditions can affect the physical properties of the cream and potentially reduce its anesthetic efficacy.
- Temperature: Store at controlled room temperature between 15°C and 30°C (59°F and 86°F). Brief excursions to temperatures up to 40°C may be tolerated but should be avoided
- Freezing: Do not freeze the cream. Freezing and thawing may disrupt the cream's emulsion and alter its consistency and drug delivery characteristics
- Light: Protect from prolonged exposure to direct sunlight and excessive heat. Store in its original tube packaging
- Tube closure: Keep the tube tightly closed after each use to prevent contamination and drying out of the cream
- Children: Keep out of the reach and sight of children. Accidental ingestion of topical lidocaine cream by a child can be dangerous
- Expiry date: Do not use after the expiration date printed on the tube and packaging. Dispose of expired medication according to your local pharmacy's take-back program or household medication disposal guidelines
- Disposal: Do not dispose of medications via household waste or wastewater. Ask your pharmacist about proper disposal methods to protect the environment
What Does Maxilene Contain?
The active ingredient in Maxilene is lidocaine 4% (40 mg per gram of cream). The inactive ingredients form the cream base and delivery system, which includes a liposomal formulation designed to enhance skin penetration and provide consistent anesthetic effect.
Understanding the full composition of Maxilene is important for patients who may have allergies or sensitivities to specific ingredients. The complete list of ingredients is as follows:
- Active ingredient: Lidocaine 4% w/w (40 mg/g)
- Inactive ingredients (excipients): Purified water, glycerin, sorbitan monostearate, polysorbate 60, cetyl alcohol, stearyl alcohol, methylparaben, propylparaben, cholesterol, and a liposomal delivery system
The cream is a white to off-white topical formulation supplied in aluminum tubes. The liposomal technology incorporated in Maxilene's formulation helps encapsulate the lidocaine molecules in microscopic lipid vesicles, which enhances penetration through the skin's outer barrier (stratum corneum) and promotes more effective delivery of the active ingredient to the target nerve endings in the dermis.
Maxilene contains parabens (methylparaben and propylparaben) as preservatives. While paraben allergy is uncommon, patients with a known sensitivity to parabens should discuss alternative topical anesthetic options with their healthcare provider. The cream also contains cetyl alcohol and stearyl alcohol, which may cause local skin reactions in sensitive individuals. If you have a history of contact allergies, inform your doctor before using this product.
Frequently Asked Questions About Maxilene
Maxilene is a topical anesthetic cream containing 4% lidocaine. It is primarily used to numb the skin before minor medical procedures such as needle insertions (blood draws, IV cannulation, vaccinations), minor surgical procedures (biopsies, mole removal), and cosmetic treatments (laser therapy, dermal fillers). It is suitable for both adults and children and works by temporarily blocking nerve signals in the area where it is applied, reducing pain and discomfort during procedures.
Maxilene typically takes 30 to 60 minutes to produce effective numbing when applied under an occlusive dressing (such as plastic wrap or a transparent adhesive bandage). Without occlusion, onset may be slower, approximately 60 to 90 minutes. The anesthetic effect lasts approximately 1 to 2 hours after the cream is removed. For optimal results, apply the cream at the recommended time before your procedure and cover it with an occlusive dressing as directed by your healthcare provider.
Yes, Maxilene can be used on children, including infants from 1 month of age, for numbing skin before needle procedures. However, the application area, amount of cream, and application duration should be carefully controlled based on the child's age and weight. In young infants and children, always use the smallest effective amount on the smallest area for the shortest time necessary. Your healthcare provider will provide specific guidance on the appropriate dose and application time for your child.
The main difference between Maxilene and EMLA cream is their active ingredients. Maxilene contains lidocaine 4% as its sole active ingredient, while EMLA contains a combination of lidocaine 2.5% and prilocaine 2.5%. Both are effective topical anesthetics, but Maxilene may be preferred in certain situations: it does not carry the risk of methemoglobinemia associated with prilocaine (particularly relevant for young infants), and it may have a shorter onset time due to its liposomal delivery system. EMLA requires a minimum application time of 60 minutes, whereas Maxilene can begin working in as little as 30 minutes under occlusion.
Maxilene should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lidocaine crosses the placenta, but systemic absorption from topical application on intact skin is minimal. There are no adequate well-controlled studies specifically on topical lidocaine use in pregnant women. The small amounts absorbed from a single topical application are generally considered unlikely to pose a significant risk. As a precaution, always consult your healthcare provider before using Maxilene if you are pregnant or planning to become pregnant.
Maxilene 4% cream is typically available as a prescription medication (Rx) in most jurisdictions. However, availability and prescription requirements can vary by country and region. Some lower-concentration lidocaine products (such as 2% or lower) may be available over the counter in certain markets. Always check with your local pharmacy or healthcare provider regarding the specific regulations in your area. Even when available without a prescription, it is advisable to use topical lidocaine products under the guidance of a healthcare professional to ensure safe and appropriate use.
References
This article is based on the following peer-reviewed sources, international guidelines, and official prescribing information:
- World Health Organization (WHO). WHO Model List of Essential Medicines - 23rd List, 2023. Geneva: WHO; 2023. Lidocaine listed as an essential medicine for local anesthesia.
- European Medicines Agency (EMA). Lidocaine - Summary of Product Characteristics. EMA; 2024. Official EU prescribing information for lidocaine-containing products.
- U.S. Food and Drug Administration (FDA). Lidocaine Topical - Drug Label Information. DailyMed/National Library of Medicine; 2024.
- British National Formulary (BNF). Lidocaine (Topical). National Institute for Health and Care Excellence (NICE); 2025. Evidence-based prescribing guidance.
- Tadicherla S, Berman B. Percutaneous dermal drug delivery for local pain control. Therapeutics and Clinical Risk Management. 2006;2(1):99-113.
- Taddio A, et al. Reducing pain during vaccine injections: clinical practice guideline. CMAJ. 2015;187(13):975-982. doi:10.1503/cmaj.150391.
- Friedman PM, et al. Topical anesthetics update: EMLA and beyond. Dermatologic Surgery. 2001;27(12):1019-1026.
- Sobanko JF, et al. Topical anesthetics for dermatologic procedures: a review. Dermatologic Surgery. 2012;38(5):709-721. doi:10.1111/j.1524-4725.2012.02345.x.
- Marra DE, et al. Lidocaine 4% cream compared with lidocaine 2.5%/prilocaine 2.5% cream for topical anesthesia in dermatologic procedures. Journal of the American Academy of Dermatology. 2006;54(1):AB35.
- Fettiplace MR, Bhana N. Lidocaine toxicity: pharmacology, prevention, and treatment. Current Anesthesiology Reports. 2018;8:140-147. doi:10.1007/s40140-018-0259-x.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, which includes board-certified physicians specializing in dermatology, anesthesiology, clinical pharmacology, and pain management.
All content is reviewed according to international medical guidelines (WHO, EMA, FDA, BNF) and the GRADE evidence framework. Our editorial process ensures accuracy, objectivity, and clinical relevance.
iMedic has no commercial funding from pharmaceutical companies. All content is independently produced and reviewed. We have no conflicts of interest to declare.